OakChart

Prenetics Global Limited

PREConsumer Defensive·Packaged Foods·Hong Kong·Micro·NASD·Nov 10 • 3:59 PM ET

17.230.00 (0.00%)
2026-11-11 15:21 CET
Market cap
291.84 USD m
Revenue, TTM
142.56 USD m
Net income, TTM
-67.61 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-4.17
P/E
-
Compare

Price

PRE against its 20, 50 and 200-day averages
2050200beatmissearnings
15.0020.0025.00476K952KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PREclose 17.2320-day 17.7650-day 20.99200-day 19.5817.23

36.7% under 27.24 on 2 Sep 2026. Last 15 sessions, 31.2% high to low

Profile

PRE
52-week range, 37% of the way up
11.3627.24

Prenetics Global Ltd. is a health sciences company, which engages in providing consumer health products and services. The firm offers scientifically formulated supplements under the IM8 brand, sports nutrition products under the Europa platform, and direct-to-consumer DNA tests through the CircleDNA brand. It is also involved in establishing a Bitcoin treasury for the exploration of applications within the healthcare ecosystem. The company was founded by Sheng Wu Yeung and Chi Hung Tzang in 2014 and has dual headquartered in Charlotte, the United States and Hong Kong.

Employees98
IPOJul 16, 2021
Beta0.40
ATR, 14d1.46
Rel volume0.00
Short float3.87%
Insider own22.64%
Inst own7.30%

Snapshot

6 groups

Valuation

Index-
Market Cap291.84M
Enterprise Value183.04M
Income-67.61M
Sales142.56M
Book/sh5.56
Cash/sh6.46
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees98
IPOJul 16, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S2.05
P/B3.10
P/C2.67
P/FCF-
EV/EBITDA-
EV/Sales1.28
Quick Ratio3.66
Current Ratio4.04
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-4.17
EPS next Y-1.76
EPS next Q-0.82
EPS this Y7.33%
EPS next Y49.79%
EPS next 5Y54.25%
EPS past 3/5Y58.51% 34.71%
Sales past 3/5Y91.46% -23.93%
EPS Y/Y TTM-5.43%
Sales Y/Y TTM182.05%
EPS Q/Q49.36%
Sales Q/Q210.67%
EarningsNov 18 BMO
EPS/Sales Surpr.36.90% -6.74%

Ownership

Insider Own22.64%
Insider Trans1.26%
Inst Own7.30%
Inst Trans-16.50%
ROA-39.86%
ROE-57.62%
ROIC-72.58%
Gross Margin63.22%
Oper. Margin-35.48%
Profit Margin-47.43%
SMA20-3.01%
SMA50-17.92%
SMA200-11.98%
Trades-

Technical

Shs Outstand15.15M
Shs Float13.10M
Short Float3.87%
Short Ratio2.30
Short Interest0.51M
52W High27.24 -36.75%
52W Low11.36 51.61%
Volatility8.83% 8.20%
ATR (14)1.46
RSI (14)42.32
Beta0.40
Rel Volume0.00
Avg Volume220.53K
Volume0

Performance

Perf Week6.42%
Perf Month-18.57%
Perf Quarter-7.76%
Perf Half Y-4.22%
Perf YTD9.40%
Perf Year44.91%
Perf 3Y237.84%
Perf 5Y-85.08%
Perf 10Y-
Recom1.00
Target Price40.56
Prev Close17.23
Price17.23
Change %0.00%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Oct 26, 2026InitiatedMMaxim GroupBuy$41+138.0%
Sep 17, 2026InitiatedCCraig HallumBuy$40+132.2%
Aug 27, 2026InitiatedRB. Riley SecuritiesBuy$37+114.7%
Jun 16, 2026InitiatedTThe Benchmark CompanyBuy$30+74.1%
Mar 16, 2026InitiatedLLake StreetBuy$29+68.3%
Feb 11, 2026InitiatedRRoth CapitalBuy$36+108.9%
Jan 18, 2023InitiatedCCantor FitzgeraldOverweight$7-59.4%

Peers

Mkt cap
TickerCompanyMkt cap
USNAUsana Health Sciences Inc242.22M
NATRNature's Sunshine Products Inc189.40M
BHSTBioHarvest Sciences Inc40.58M
ENHAEnhanced Group Inc314.94M
FTLFFitLife Brands Inc75.97M
LFVNLifevantage Corp57.83M
BRBRBellring Brands Inc1.18B
HLFHerbalife Ltd1.64B
NUSNu Skin Enterprises Inc199.58M
HIMSHims & Hers Health Inc4.53B

Insider trading

14 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Leogrande Hudson BlakeDirectorNov 04 '26Option Exercise0.002,000010,001Nov 05 08:53 AM
Leogrande Hudson BlakeDirectorOct 04 '26Option Exercise0.002,00008,001Oct 06 06:01 AM
Lo Hoi ChunChief Financial OfficerSep 30 '26Option Exercise0.007,6350573,648Oct 02 08:36 AM
Leogrande Hudson BlakeDirectorSep 04 '26Option Exercise0.002,00006,001Sep 04 08:44 AM
Rosin Brian JCFO of IM8 (US) LLCAug 24 '26Buy21.1918,000381,42018,000Aug 26 08:23 AM
Rosin Brian JCFO of IM8 (US) LLCAug 25 '26Buy22.805,100116,28023,100Aug 26 08:23 AM
Lo Hoi ChunChief Financial OfficerAug 21 '26Option Exercise0.0078,5513566,013Aug 24 09:43 PM
Yeung Danny Sheng WuChief Executive OfficerAug 20 '26Option Exercise0.0053,9535137,647Aug 24 09:41 PM
Yeung Danny Sheng WuChief Executive OfficerAug 24 '26Buy21.2317,181364,673112,416Aug 24 09:41 PM
Yeung Danny Sheng WuChief Executive OfficerAug 20 '26Buy18.317,500137,32595,235Aug 24 09:41 PM
Leogrande Hudson BlakeDirectorAug 04 '26Option Exercise0.002,00104,001Aug 05 10:45 AM
Leogrande Hudson BlakeDirectorJul 04 '26Option Exercise0.002,00002,000Jul 07 07:35 AM
Cheng Yin PanDirectorJun 15 '26Option Exercise0.0015,873059,051Jun 16 09:10 AM
VANDERVEEN DAVIDDirectorJun 15 '26Option Exercise0.006,944045,249Jun 16 08:38 AM

Held by

AUM
TickerCompanyAUM
GWXState Street SPDR S&P International Small Cap ETFAUM: 906.57M
RUSCRussell Investments U.S. Small Cap Equity ETFAUM: 85.35M

News

latest 14 of 206
  • Prenetics Must Prove July's Record IM8 Momentum Held As Street Trails Raised Guidance (Earnings Whispers)
  • Care Bears And Prenetics' IM8 Announce Global Partnership (PR Newswire)
  • Prenetics' IM8 and Authentic Brands Group Announce 10-Year Exclusive Global Partnership to Create Care Bears by IM8; Authentic to Become Strategic Shareholder in Prenetics (GlobeNewswire)
  • Prenetics' IM8 Names Brian J. Rosin as Successor Chief Financial Officer (GlobeNewswire)
  • IM8 Named Official Nutrition Partner of the NBA in Australia and Southeast Asia (GlobeNewswire)
  • Loading…
  • Prenetics' IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results (GlobeNewswire) +10.88%
  • Prenetics Global Ltd (PRE) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ... (GuruFocus.com) +12.41%
  • Prenetics' IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership (GlobeNewswire)
  • Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220-230 Million; July Was the First Month of Positive Consolidated Adjusted Free Cash Flow and Expected to Remain Positive for Q3 and Beyond (GlobeNewswire)
  • Earnings To Watch: Prenetics Global Ltd (PRE) Q2 2026 -- GF Value Sees 256% Upside (GuruFocus.com)
  • Prenetics, Parent of IM8, Appoints II Ranked, Caroline Levy, Veteran Wall Street Consumer Analyst as Independent Director (GlobeNewswire)
  • Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation (GlobeNewswire)
  • Prenetics' IM8 Secures $1 Billion Growth Financing from General Catalyst's Customer Value Fund (CVF) (GlobeNewswire) +13.70%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-18--0.820--63.189
2026Q22026-08-18-0.530-0.840-0.52046.4949.854
2026Q12026-06-10-1.360-1.017-1.36035.9536.003
2025Q42026-02-18-1.770-0.330-1.75436.6033.433
2025Q32025-11-10-0.410-0.550-0.53323.5626.001
2025Q22025-09-12-0.820-0.710-1.02817.6821.701
2025Q12025-06-12-0.800-0.800-0.79917.3012.001
2024Q42025-03-05-0.940-0.720-1.28710.5012.401
2024Q32024-11-27-0.840-0.860-0.8397.789.201
2024Q22024-10-07-0.754-0.930-0.8775.947.701
2024Q12024-06-18-0.378-1.020-0.7016.416.201
2023Q42024-04-01-0.512-4.800-1.5725.437.501
2023Q32023-11-20-0.049-1.200-1.1564.8710.201
2023Q22023-09-15-0.756-0.900-2.0585.7022.671
2023Q12023-06-05-0.599-0.750-0.98817.7026.542
2022Q42023-03-141.262-1.3500.14852.3254.442

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-178.8--14.771275.85-
2022FY7.735-32.988-37.570275.76289.15
2023FY-2.525-21.150-5.57721.7435.80
2024FY-3.520-3.300-3.70630.6032.60
2025FY-3.790-2.517-4.15092.4090.14
2026FY--3.512--224.11
2027FY--1.763--406.7
2028FY--0.363--531.8
2029FY-1.380--695.31
2030FY-2.620--780.98

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-0491063.1862.4063.80
2026Q3S2026-11-0181063.2862.7063.80
2026Q3S2026-10-2383063.2862.7063.80
2026Q3S2026-09-2763063.2562.7063.80
2026Q3S2026-09-1664063.2562.7063.80
2026Q3S2026-09-0454063.3663.0063.80
2026Q3S2026-08-2554063.0862.1063.80
2026Q3S2026-08-1844063.1062.1063.80
2026Q3S2026-07-1544061.9861.0063.00
2026Q3S2026-07-1444060.2354.8063.00
2026Q3S2026-06-1853054.3549.4758.50
2026Q3S2026-06-1553054.1549.4758.50
2026Q3S2026-06-1043053.2349.4758.50
2026Q3S2026-05-1444053.2349.4758.50

Estimate history

EPS, annual-14.771-37.57-5.577-3.706-2.684-4.1673
Period20212022202320242025TTM
EPS, quarterly-0.877-0.839-1.287-0.799-1.028-0.533-1.754-1.361-0.52
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual275.85313.16421.74315.93692.39142.56
Period20212022202320242025TTM
Sales, quarterly5.9427.77810.48817.31214.96423.55536.55835.95446.488
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual11.7819.13212.20512.84516.73116.731
Period20212022202320242025MRQ
Shares, quarterly12.21712.21712.84512.07712.07712.89416.73116.73116.731
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue142.5692.3915.9421.7413.16275.85
Cost of Goods Sold Incl. D&A53.3045.848.8712.919.55169.72
Gross Profit90.1246.557.078.833.62106.13
Selling, General and Administrative Excl. Other139.8384.8345.3461.3470.07116.49
Research and Development4.115.048.8811.665.9910.56
Other Operating Expense0.000.000.000.000.000.00
Operating Income-50.58-38.28-38.28-52.51-66.45-10.36
Interest Expense0.120.240.170.123.995.24
Unusual Expense24.34-2.958.827.68155.80154.70
Net Income Before Taxes-70.59-34.95-44.02-55.81-225.82-170.28
Income Taxes0.090.03-7.64-0.27-0.243.73
Consolidated Net Income-71.63-36.25-38.39-56.40-225.58-174.02
Net Income From Continuing Operations-70.30-33.98-34.88-54.35-225.58-174.01
Net Income-67.61-37.71-46.30-62.72-190.45-174.01
EPS (Recurring)-2.93-2.83-3.21-5.10-16.06-5.58
EPS (Basic, Before Extraordinaries)-4.17-2.68-3.71-5.58-37.57-14.77
EPS (Diluted)-4.17-2.68-3.71-5.58-37.57-14.77
EBITDA--35.94-35.80-44.72-58.91-3.01
Non-Operating Income (Expense)4.450.613.254.510.430.02
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense3.954.295.3610.5931.5816.42
Price To Sales Ratio2.322.404.553.0611.554.92
Gross Margin63.2250.3944.3540.6127.4938.47
Operating Margin-35.48-41.43-240.19-241.52-504.79-3.75
Net Margin-47.43-40.82-290.56-288.48-1,446.79-63.08
Shares Outstanding16.7316.7312.8412.219.1311.78
Market Capitalization291.84291.8470.8671.03221.96561.44

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue46.4935.9536.5623.5514.9617.3110.497.78
Cost of Goods Sold Incl. D&A16.2912.6714.829.539.139.976.595.55
Gross Profit30.2023.2821.7414.025.837.343.902.23
Selling, General and Administrative Excl. Other52.1232.9934.1320.5813.3318.2921.7613.99
Research and Development0.761.440.741.170.802.422.582.59
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-21.92-9.71-12.39-6.56-7.49-10.94-17.86-11.76
Interest Expense0.010.010.050.060.070.070.080.08
Unusual Expense-11.9118.4317.91-0.100.740.068.70-0.11
Net Income Before Taxes-9.08-27.31-28.08-6.12-8.60-10.76-24.10-11.78
Income Taxes0.010.030.040.010.05-0.06-7.42-0.08
Consolidated Net Income-9.09-27.34-28.41-6.79-8.76-11.01-17.55-12.04
Net Income From Continuing Operations-9.09-27.34-28.37-5.50-8.44-10.38-16.35-10.64
Net Income-8.98-23.10-28.12-7.41-12.41-10.39-16.34-10.67
EPS (Recurring)-1.00-0.60-0.97-0.54-0.98-0.80-0.81-0.84
EPS (Basic, Before Extraordinaries)-0.52-1.36-1.75-0.53-1.03-0.80-1.29-0.84
EPS (Diluted)-0.52-1.36-1.75-0.53-1.03-0.80-1.29-0.84
EBITDA-21.73-9.52-11.90--5.93-9.82--8.32
Non-Operating Income (Expense)0.940.842.270.40-0.300.312.54-0.05
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.641.000.591.721.150.867.351.20
Price To Sales Ratio2.322.962.732.792.031.232.401.99
Gross Margin64.9764.7659.4759.5438.9942.4137.2028.64
Operating Margin-47.15-27.00-33.89-27.85-50.06-63.22-170.30-151.19
Net Margin-19.32-64.26-76.91-31.45-82.93-60.02-155.81-137.21
Shares Outstanding16.7316.7316.7312.8912.0812.0812.8412.22
Market Capitalization291.84325.13222.17173.35110.9847.8970.8648.87

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments63.3262.8172.74184.1245.19
Short Term Receivables4.295.615.1642.5047.05
Inventories7.036.573.134.536.83
Other Current Assets10.557.624.326.097.82
Total Current Assets85.2082.6085.35237.23106.89
Net Property, Plant & Equipment1.767.815.7813.1013.04
Total Investments and Advances66.3669.33107.840.790.00
Intangible Assets46.0748.9442.5948.5927.80
Deferred Tax Assets-0.000.030.240.08
Other Assets6.684.9012.5912.180.69
Total Assets206.07213.57254.17312.13148.51
Short Term Debt Incl. Current Port. of LT Debt1.332.761.502.881.67
Accounts Payable3.143.671.677.299.98
Income Tax Payable0.030.017.408.601.22
Other Current Liabilities24.2130.1128.9138.4245.87
Total Current Liabilities28.7136.5539.4857.2058.74
Long Term Debt0.443.010.873.76490.01
Provision for Risks Charges0.000.000.000.000.00
Deferred Tax Liabilities0.012.172.613.190.66
Other Liabilities20.550.501.054.520.00
Total Liabilities49.7142.2344.0168.67549.40
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity156.46170.39206.36237.06-400.81
Total Shareholders Equity156.46170.39206.36237.06-400.81
Accumulated Minority Interest-0.090.963.806.40-0.08
Total Equity156.37171.35210.16243.46-400.89
Total Liabilities & Stockholders Equity206.07213.57254.17312.13148.51
Book Value Per Share9.3513.2716.9125.96-34.02
Tangible Book Value Per Share6.609.4613.4220.64-36.38
Full-Time Employees982853243971
Price to Book Ratio3.100.400.321.071.80
Return on Assets-16.19-14.92-19.19-97.94-
Return on Equity-20.79-18.52-24.51-69.34-
Return on Invested Capital-24.03-26.70-30.27-79.08-195.09
Quick Ratio2.722.082.084.071.70
Current Ratio2.972.262.164.151.82

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income--39.98-49.81-64.78-190.45-174.02
Depreciation-3.785.937.797.547.35
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00
Other Funds (Non Cash)-6.3315.0822.95231.50186.66
Funds from Operations--29.87-28.80-34.0348.5919.99
Extraordinary Item-0.000.000.000.000.00
Changes in Working Capital-9.131.9724.21-33.76-6.57
Cash from Operating Activities--20.73-26.84-9.8214.8213.42
Capital Expenditures--54.56-1.07-0.91-6.34-11.41
Net Assets From Acquisitions-0.00-8.350.00-3.420.00
Sale of Fixed Assets and Businesses-37.780.040.100.050.71
Purchase or Sale of Investments--20.0029.87-10.00-17.00-10.00
Purchase of Investments--20.00-0.13-10.00-20.00-10.00
Sale Or Maturity of Investments-0.0030.000.003.000.00
Other Uses-0.000.00-96.00-19.92-1.33
Other Sources-0.0016.0019.920.000.00
Cash from Investing Activities--36.7936.50-86.89-46.63-22.03
Cash Dividends Paid-0.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Change in Capital Stock-0.00-0.58-1.23-0.5425.97
Repurchase of Common Pref Stock-0.00-0.58-1.23-0.660.00
Sale of Common Pref Stock-0.000.000.000.1225.97
Proceedsfrom Stock Options-0.000.000.000.1225.97
Issuance or Reduction of Debt, Net-0.000.000.000.000.00
Change in Long Term Debt-0.000.000.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.00
Net Financing Active Other Cash Flow-40.150.000.00146.164.85
Other Financing Activities Uses-0.000.000.000.00-0.13
Cash from Financing Activities-37.47-3.34-4.70143.4929.32
Exchange Rate Effect--0.070.220.47-0.320.09
Net Change in Cash--20.126.55-100.95111.3720.80
Free Cash Flow--20.94-27.84-10.179.884.87
Price to Free Cash Flow----15.40278.55

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments109.39106.0363.3223.7327.7158.53
Short Term Receivables5.132.534.291.791.874.46
Inventories13.9914.207.035.344.306.61
Other Current Assets19.169.3510.557.4210.166.93
Total Current Assets147.68132.1185.2038.2844.0476.53
Net Property, Plant & Equipment0.750.591.762.212.747.07
Total Investments and Advances4.642.3466.3667.3767.8068.99
Intangible Assets0.020.0446.078.368.4748.70
Other Assets0.5640.226.6880.2976.062.73
Total Assets153.66175.30206.07196.51199.11204.01
Short Term Debt Incl. Current Port. of LT Debt0.540.411.331.431.532.60
Accounts Payable1.031.963.145.924.964.14
Income Tax Payable0.030.030.030.000.010.01
Other Current Liabilities34.9623.2424.2117.9315.3130.94
Total Current Liabilities36.5625.6428.7125.2821.8137.70
Long Term Debt0.140.050.440.681.052.55
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.010.010.010.010.012.10
Other Liabilities24.0228.5820.559.3425.350.56
Total Liabilities60.7354.2849.7135.3048.2142.90
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity93.01121.11156.46161.29150.98160.88
Total Shareholders Equity93.01121.11156.46161.29150.98160.88
Accumulated Minority Interest-0.09-0.09-0.09-0.09-0.090.23
Total Equity92.92121.02156.37161.20150.89161.12
Total Liabilities & Stockholders Equity153.66175.30206.07196.51199.11204.01
Book Value Per Share5.567.249.3512.5112.5013.32
Tangible Book Value Per Share5.567.246.6011.8611.809.29
Full-Time Employees--98---
Price to Book Ratio3.101.541.261.060.640.27
Return on Assets-39.86-36.72-25.11-18.82-21.19-21.52
Return on Equity-57.62-49.40-32.24-23.93-27.01-26.74
Return on Invested Capital-9.64-19.07-17.92-4.57-8.16-6.36
Quick Ratio3.664.602.721.301.821.85
Current Ratio4.045.152.971.512.022.03

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-8.98-23.11----
Depreciation0.190.18----
Other Funds (Non Cash)-9.9715.32----
Funds from Operations-18.76-7.60----
Extraordinary Item0.000.00----
Changes in Working Capital3.30-4.23----
Cash from Operating Activities-15.45-11.83----
Capital Expenditures0.000.00----
Net Assets From Acquisitions0.000.00----
Sale of Fixed Assets and Businesses0.0069.00----
Purchase or Sale of Investments0.00-19.88----
Purchase of Investments0.00-19.88----
Other Uses0.000.00----
Other Sources41.340.00----
Cash from Investing Activities41.3449.12----
Cash Dividends Paid0.000.00----
Preferred Dividends (Cash Flow)0.000.00----
Change in Capital Stock-24.86-13.12----
Repurchase of Common Pref Stock-26.92-13.12----
Sale of Common Pref Stock2.060.00----
Proceedsfrom Stock Options2.060.00----
Issuance or Reduction of Debt, Net0.000.00----
Change in Long Term Debt0.000.00----
Issuance of Long Term Debt0.000.00----
Reduction of Long Term Debt0.000.00----
Net Financing Active Other Cash Flow2.120.00----
Other Financing Activities Uses0.000.00----
Cash from Financing Activities-22.86-13.27----
Exchange Rate Effect0.01-0.14----
Net Change in Cash3.0323.89----

Revenue breakdown

Customer Health - Health And Wellness Solutions2024: 370.00K
Customer Health - Sport Distribution2024: 5.20M
Diagnostics - Cancer Treatment2024: 14.69M
Prevention - Genetic Testing2024: 10.37M
Total Pharmaceutical Preparations revenue2025: 92.39M
Hong Kong2024: 14.27M 2025: 92.39M
Rest Of The World2024: 972.00K
Taiwan2024: 7.09M
United Kingdom2024: 2.78M
United States2024: 5.51M
Consumer Health2024: 5.57M
Diagnostics2024: 14.69M
Prevention2024: 10.37M
Total Pharmaceutical Preparations revenue2025: 92.39M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.87%0.5M13.1M209.17K
2026-10-153.93%0.5M13.1M216.43K
2026-09-303.33%0.4M13.3M226.54K
2026-09-153.89%0.5M13.3M219.33K
2026-08-314.50%0.6M13.3M235.52K
2026-08-144.41%0.6M13.4M222.86K
2026-07-315.05%0.7M13.0M237.52K
2026-07-155.24%0.7M12.7M231.19K
2026-06-304.39%0.6M12.7M208.45K
2026-06-154.76%0.6M12.7M215.31K
2026-05-296.61%0.8M12.7M211.63K
2026-05-155.25%0.6M12.2M221.75K
2026-04-305.29%0.6M12.2M230.78K
2026-04-155.34%0.6M11.4M250.10K
2026-03-314.75%0.6M12.1M261.72K
2026-03-134.52%0.5M12.1M254.80K
2026-02-273.95%0.5M12.1M232.45K
2026-02-132.79%0.3M12.1M195.05K
2026-01-300.91%0.1M12.1M175.87K
2026-01-152.31%0.2M9.9M168.20K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.0018.95-1.000.00---
call5.000.000.0016.67-4.000.00---
call7.500.000.000.00-0.000.00---
call10.000.000.009.11-80.000.00---
call12.500.000.006.80-11.000.00---
call15.000.000.002.90-65.000.00---
call17.500.000.000.41-78.000.00---
call20.000.000.001.30-4370.00---
call22.500.000.000.10-11.000.00---
call25.000.000.002.02-1380.00---
call30.000.000.001.05-1530.00---
call35.000.000.002.50-10.000.00---
call40.000.000.001.65-1.000.00---
put2.500.000.000.00-0.000.00---
put5.000.000.000.00-0.000.00---
put7.500.000.000.00-0.000.00---
put10.000.000.000.00-0.000.00---
put12.500.000.000.30-10.000.00---
put15.000.000.000.75-16.000.00---
put17.500.000.001.00-71.000.00---
put20.000.000.002.00-17.000.00---
put22.500.000.003.35-6.000.00---
put25.000.000.004.30-0.000.00---
put30.000.000.0016.25-10.000.00---
put35.000.000.000.00-0.000.00---
put40.000.000.000.00-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-054Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-05SEC
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-03SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-30SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-12SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-04SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-22F-1/ASEC
2026-09-08F-1/ASEC
2026-09-0420-F/A2025-12-31SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-08-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-26SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-263Initial statement of beneficial ownership of securities2026-08-17SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-21S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-20SEC
2026-08-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-17SEC
2026-08-123Initial statement of beneficial ownership of securities2026-08-03SEC
2026-08-07F-1/ASEC
2026-08-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-07SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-07-3020-F/A2025-12-31SEC
2026-07-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-14SEC
2026-07-103Initial statement of beneficial ownership of securities2026-07-10SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-04SEC
2026-07-0220-F/A2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08999.70K400
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Prospect Capital Advisors, LLC1.40%
JANE STREET GROUP, LLC1.34%
GOLDMAN SACHS GROUP INC1.00%
MILLENNIUM MANAGEMENT LLC0.75%
Tenzing Global Management, LLC0.74%
MARSHALL WACE, LLP0.28%
NOMURA HOLDINGS INC0.25%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.23%
XTX Topco Ltd0.18%
STEVENS CAPITAL PARTNERS0.18%

Funds

Fund% owned
Morningstar Total Return Bond Fund3.44%
MEDIUM-DURATION BOND FUND2.38%
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated1.19%
Avantis Emerging Markets Equity ETF0.98%
Flaherty & Crumrine Dynamic Preferred and Income Fund Incorporated0.87%
Guggenheim Strategic Opportunities Fund0.75%
Flaherty & Crumrine Total Return Fund Incorporated0.28%
Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust0.27%
Flaherty & Crumrine Preferred and Income Fund Incorporated0.22%
Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated0.19%

OakChart. PRE. Cached 15 minutes.